Trials. Conclusion: The current study provides potential a reference for the security of LHQW. Inhibitory effects of three prescriptions of traditional Chinese medicine on SARS-associated coronavirus, http://kns.cnki.net/kcms/detail/11.2162.R.20200422.1429.002.html. Li X., Yang Y., Liu L., Yang X., Zhao X., Li Y., Ge Y., Shi Y., Lv P., Zhang J., Bai T., Zhou H., Luo P., Huang S. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019. Though the quality of the included literature was mixed, the lung protection effects of LHQW was demonstrated. There was no statistically significant difference in the incidence of adverse reactions during treatment of herpes zoster between the LHQW group and the conventional drug group (RR = 0.80, 95% CI = 0.521.23, p = 0.302). (2021). COVID-19 pandemic has caused a serious threat to public health and become the greatest challenge facing the world. Guo H., Zhang Q.H., Yang J., Gong J.N., Zhao Y.S., Zhou X.P. Among the 13 included studies on treatment of hand-foot-mouth disease, eight reported adverse reactions. The documents were filtered and summarized for final evaluation. 339 (7), b2535. Role of LHQW in the treatment of COVID-19. The quantitative analysis of all eligible studies. 12, 640782. doi:10.3389/fphar.2021.640782. Res. ADVERSE REACTION Uncertainty. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Keywords: Lianhua Qingwen, adverse reaction, COVID-19, influenza, traditional Chinese medicine, meta-analysis, Citation: Hu C, He B, Gong F, Liang M, Zhao D and Zhang G (2022) The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis. Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19 Mo H.Y., Yang Z.F., Zheng J.P., Mo Z.Y., Li Y.M., Xiao Z.L. Twelve representative compounds were further quantified as chemical markers, including amygdalin, forsythoside E, salidroside, glycyrrhizic acid, chlorogenic acid, hyperin, rutin, forsythoside A, cryptochlorogenic acid, sweroside, phillyrin, and rhein (Jia et al., 2015). Available at: http://www.theplantlist.org/(Accessed December 18, 2021). The recent network pharmacology studies showed that the effects of LHQW prescription was related to virus infection, inflammation and immunity, moreover, its main active ingredients were verified by molecular docking with angiotensin-converting enzyme 2 (ACE2), one receptor of SARS-CoV-2, so as to have a therapeutic effect on COVID-19 [[27], [28], [29]]. It cannot be taken as prophylaxis or as a health supplement. Recent data also showed that LHQW played a vigorous role in COVID-19 treatment. 26 (11), 812. Traditional Chinese medicine Lianhua Qingwen treating corona - PLOS Qualitative and Quantitative Analysis of the Major Constituents in Chinese Medical Preparation Lianhua-Qingwen Capsule by UPLC-DAD-QTOF-MS. ScientificWorldJournal. Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. Lianhua Qingwen, the traditional Chinese medicine recently approved for use in the Philippines by the country's Food and Drugs Administration (FDA), only treats symptoms of the coronavirus disease 2019 (COVID-19), and not the disease itself, a traditional Chinese medicine physician said Tuesday. Li Q., Yin J., Ran Q.S., Yang Q., Liu L., Zhao Z., Li Y.J., Chen Y., Sun L.D., Wang Y.J., Weng X.G., Cai W.Y., Zhu X.X. Contraindications . Pulmonary Rale.Eighteen studies reported an effect on the duration of pulmonary rale. Advances in Pharmacology and Clinical Research of Lianhua Qingwen Capsules. A recent clinical trial including 36 common cold with wind-heat syndrome patients demonstrated that LHQW (three times daily for four days) treatment could significantly reduce TCM symptom score, with the median time to fever relief of (45) h and the median time to fever clearance of 36h [35]. 17 (13), 6264. The Trim and Fill method was further applied to assess the impact of publication bias. Subgroup analysis additionally revealed a reduced incidence of some adverse reactions in the LHQW group compared to the conventional drug group (Rash of skin and its appendage damage, dizziness or headache owing to nervous system damage, nausea or vomiting from gastrointestinal system damage and resurgence of disease from other adverse reactions). Study supervision and funding were done by GZ. There was no statistically significant difference in the incidence of adverse reactions during treatment of hand-foot-mouth disease between the LHQW group and the conventional drug group (RR = 0.53, 95% CI = 0.221.30, p = 0.165). Business China. From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment. Few reports of adverse reactions in the course of treating COVID-19 pneumonia with LHQW are available. We hope this review will not only present comprehensive evidence for LHQW use in COVID-19 therapy, but also fuel antiviral researches and put forward promising insights for further antiviral drug development. Further investigation confirmed that the combination treatment of LHQW capsules (200mg/kg/day) with oseltamivir (2mg/kg/day) markedly reduced IBV infection over the individual administration of either alone in vivo, proving that LHQW capsules could be used as an assistant drug to enhance the effect of oseltamivir against IBV infection [26]. These above ingredients are decocted, distilled, filtered, refrigerated, mixed well with powdered sugar, dextrin or starch, dried and finally made into LHQW (Chinese Pharmacopoeia, 2020). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. Warning 1. f. & Thoms.) Lianhua Qingwen combined with conventional treatment obviously improved COVID-19. 48 (3), 737762. In treating fine particulates PM2.5 (7.5mg/kg)-exposed model rats, LHQW significantly relieved the pathological changes of thickened alveolar septum, congestion of capillary, interstitial edema and infiltration of lymphocyte and neutrophil surrounding bronchiole [34]. (2015). Furthermore, we also found that LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group. For thousands of years, traditional Chinese medicine (TCM) plays an important role in treating human diseases [[9], [10], [11], [12], [13], [14]]. [Systematic review of efficacy and safety of Lianhua Qingwen - PubMed Pharmacol. doi:10.1016/0197-2456(86)90046-2, Duval, S., and Tweedie, R. (2000). COVID-19: TCM Lianhua Qingwen speeds up recovery but no effect in Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. Wang S.H., Liu J.F., Zhang Y.L., Dong Z. The risk ratio (RR) and 95% confidence interval (CI) were calculated for categorical variables. The COVID-19 pneumonia epidemic has spread across the globe poses a significant challenge to public health worldwide. There was no statistically significant difference in the incidence of abnormal white blood cells and reticuloendothelial system between the LHQW group and the conventional drug group (RR = 1.00, 95% CI = 0.382.62, p = 1.000). The search keywords for screening the literature information were virus, COVID-19, or SARS-CoV-2, and Lianhua Qingwen. [3], Lianhua Qingwen was developed by Shijiazhuang Yiling Pharmaceutical in 2003 as a treatment for severe acute respiratory syndrome (SARS) following the outbreak of the disease in 2002 and was listed by the National Health Commission of China in 2004 as a treatment for influenza and other respiratory disease. China Central Television News (2020). doi:10.1097/MD.0000000000026059, Gallelli, L., Ferreri, G., Colosimo, M., Pirritano, D., Guadagnino, L., Pelaia, G., et al. 81703740), the Zhejiang Provincial Natural Science Foundation of China (No. Vahl [Oleaceae; Forsythiae Fructus], Lonicera japonica Thunb. [12], In April 2022, the Financial Times reported that the leading COVID-19 health official in the PRC, the famous epidemiologist and pulmonologist Zhong Nanshan - who has also been the most prominent scientific promoter of Lianhua Qingwen - had undisclosed prior investments in large stakeholdings in corporations producing Lianhua Qingwen and other treatments under question. 2015, 731765. doi:10.1155/2015/731765, Jin, L., Xu, Y., and Yuan, H. (2020). (Nat. Dang Y., Xu J., Yang Y., Li C., Zhang Q., Zhou W., Zhang L., Ji G. Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine. Therefore, studies with blinded participants and personnel and blinded outcome assessments were classified as low risk of bias. In terms of incomplete outcome data and selective reporting, the majority of studies reported complete data on all symptom indicators with a low risk of attrition and reporting bias. Therefore, we conducted a systematic review of the . However, in evaluation of security index, Eggers test and funnel plot analyses disclosed the existence of publication bias with regard to hepatobiliary system damage, psychiatric disorders, gastrointestinal system damage and body as a whole-general disorders. The China National Medical Products Administration agency has officially approved LHQW for the treatment of mild or ordinary COVID-19 pneumonia (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). Systematic Review Registration: https://clinicaltrials.gov/, CRD-42020224180. Dong L., Xia J.W., Gong Y., Chen Z., Yang H.H., Zhang J., He J., Chen X.D. In this analysis, the incidence of adverse reactions during treatment of influenza was lower in the LHQW group compared to the conventional drug group (RR = 0.74, 95% CI = 0.630.87, p < 0.001). Drug Related Hospital Admissions: the Role of Definitions and Intensity of Data Collection, and the Possibility of Prevention. doi:10.5582/ddt.2020.03008, PubMed Abstract | CrossRef Full Text | Google Scholar, Cao, B., Zhang, D., and Wang, C. (2020). In the evaluation of security indexes, our meta-analysis revealed that LHQW group having a lower level of adverse reactions compared to the conventional drug group, such as respiratory system damage, skin and its appendage damage, nervous system damage, gastrointestinal system damage and other adverse reactions. 20 studies documented other adverse reactions. For pooled studies, the incidence of adverse reactions was lower in the LHQW group than the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). Effects of Four Types of Integrated Chinese and Western Medicines for the Treatment of Covid-19 in china: a Network Meta-Analysis. These in vitro studies indicate that LHQW shows a wide range of antiviral activities including its anti-SARS-CoV-2 role. No adverse treatment-related effects were reported in all the included publications (from 2009 to 2011). 132 studies documented gastrointestinal system damage. In recent years, LHQW has been registered to obtain marketing authorization in Canada, Brazil, Singapore, Thailand, the Philippines, Kuwait and other countries under the designation Chinese patent medicine, medicine, physical natural health products, food supplement, modern botanical medicine or natural medicine (Yiling Pharmaceutical, 2020). Lu Y., Yang J., Wang X., Ma Z., Li S., Liu Z., Fan X. Lianhua Qingwen Prescription is approved for the treatment of fever, cough, and fatigue caused by light and common type of COVID-19 . On March 27, 2019, Yiling Pharmaceutical Co. Ltd. amended the LHQW drug manual to include adverse reactions related to its clinical application. In the evaluation of treating disease, significant reduced incidence of adverse reactions during treatment of influenza A (H1N1) and influenza were detected in the LHQW group. "It's the first time in the world that we have enough evidence to prove Lianhua Qingwen capsule is effective and can help . Experimental study on prevention and treatment of influenza virus FM1 infection in mice by Lianhua Qingwen capsule. Drug Discov. Liu Y., Liu L., Cao M.M., Wen J., Zhou S., Jiang H., Zhang Y., Zhao R.S., Yang Y.H. Front. Available at: https://chemrxiv.org/engage/chemrxiv/article-details/60c74908ee301c485bc799cf (Accessed July 23, 2021). (2020). Lianhua Qingwen Capsules of Yiling Pharmaceutical Approved in mauritius. It includes Forsythia suspensa (Thunb.) [18], In Singapore, the Health Sciences Authority has issued an advisory to clarify that although it has been approved for sale as a Chinese proprietary medicine for the relief of cold and flu symptoms, Lianhua Qingwen is not approved to treat or alleviate symptoms of COVID-19. It blocked the early stages (02h) of virus infection, and reduced virus-induced nuclear factor-kappa B (NF-B) activation and the gene expression of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-, interferon-inducible protein (IP)-10, and monocyte chemoattractant protein (MCP)-1 [24]. For rheum, sample size could partially explain heterogeneity (p = 0.005), but not year of publication (p = 0.658) and treatment of the control group (p = 0.712). Traditional Chinese medicine formulation used for the treatment of influenza, Uses and controversies of Lianhua Qingwen in relation to COVID-19, by region, "How traditional Chinese medicine TCM is used to treat Covid-19", "The mechanisms and clinical application of Traditional Chinese Medicine Lianhua-Qingwen capsule", "Clinical applications and pharmacological research progress of Lianhua Qingwen capsules/granules", "Traditional Chinese cures battle for acceptance in COVID-19 fight", "Chinese traditional medicine for Covid-19 becomes money tree", "Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis", "Doctors warn against claims that Beijing-touted health supplement distributed in Canada treats COVID-19", "The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis", "Beijing pushes traditional Chinese medicine as coronavirus treatment", "China Covid-19 tsar pushed treatments without revealing business ties", "Efficacy and Safety of Lianhuaqingwen Capsules, a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A multicenter, prospective, randomized controlled trial", "Prominent Chinese scientist failed to disclose company ties in COVID-19 clinical trial paper", "DOH and FDA Clarify Claims on the Approval of Potential COVID-19 Treatments and Calls for Resignation of the SoH", "Lianhua Qingwen, the FDA-approved traditional Chinese med, only treats symptoms, not COVID", "HSA Advisory on Lianhua Qingwen Products for Prevention or Treatment of COVID-19", "Fraudulent Coronavirus Disease 2019 (COVID-19) Products", "Chinese medicine Lianhua Qingwen makes its way into community for COVID-19 treatment despite Australian ban", https://en.wikipedia.org/w/index.php?title=Lianhua_Qingwen&oldid=1143380058, Short description is different from Wikidata, Articles needing expert attention from January 2023, Medicine articles needing expert attention, Articles containing simplified Chinese-language text, Articles containing traditional Chinese-language text, Articles with unsourced statements from August 2022, Creative Commons Attribution-ShareAlike License 3.0, Treatment against various respiratory diseases including, This page was last edited on 7 March 2023, at 11:01. doi:10.1016/s1043661802002104, Hallas, J., Harvald, B., Gram, L. F., Grodum, E., Brsen, K., Haghfelt, T., et al. Combined with western medicine conventional therapy in the treatment of 63 suspected cases of Coronavirus Disease 2019. With gradual improvement of the adverse drug reaction monitoring system of China, reports of adverse reactions or events have increased. (japanese honeysuckle) flower 27.41 mg, gypsu . The current. Drugs and Clinic. Recent advances have discovered that COVID-19 is a systematic disease targeting the lungs, vasculatures, and immune system, and involves severe lung inflammation and immune deficiency in terms of cytokine storm, neutrophil extracellular traps, as well as imbalance of lymphocyte subsets and so forth [[4], [5], [6]]. No meta-regression was performed for COVID-19 pneumonia due to the limited number of studies. Use Overdosage Contraindications Special Precautions Adverse Reactions Storage MIMS Class ATC . Based Complement. showed that the usual treatment in combination with LHQW capsules (4 capsules thrice daily for 14 days) had significantly higher recovery rate, and shorter median time to symptom recovery, as compared with control group [43]. The search keywords for screening the literature information were virus, COVID-19, or SARS-CoV-2, and Lianhua Qingwen. Frontiers | Broad Anti-Viral Capacities of Lian-Hua-Qing-Wen Capsule Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. The complex components of LHQW stand for multiple targets and pleiotropic effects, but may also lead to more ADRs. (Gancao) with a herbal ratio of 170 g: 170 g: 57g: 57g: 170 g: 170 g: 170 g: 170 g: 57g: 34 g: 57g: 5 g: 57g, which is recorded in Chinese Pharmacopeia (2015 Edition). Formulae. Considerable research to date has focused on the clinical efficacy of LHQW, the safety of LHQW is additionally an important consideration for clinical application that should not be neglected. Chinese drug Lianhua Qingwen not to be taken without doctor's OK Yang C.X., Qu J., Liu Y.T., Meng S.W., Wang B.L., Feng M.Q., Sun Y. Lianhua Qingwen - Wikipedia Ni L., Zhou L., Zhou M., Zhao J., Wang D.W. Wu, L., Chen, Y., Ma, Y., Yang, Z., Yang, N., Deng, W., et al. Ther. Evid. official website and that any information you provide is encrypted In addition to western medicine, the potential adverse drug reactions (ADRs) can not be ignored. An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency over the world. Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. A Trial of Lopinavir-Ritonavir in Covid-19. Efficacy of Huoxiang Zhengqi Dropping Pills and Lianhua Qingwen Granules in Treatment of Covid-19: a Randomized Controlled Trial. Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review. Liu, X. Y. LHQW prescription (capsules type, or granules type) consists of 11 herbs, gypsum and menthol [18]. and transmitted securely. Res. Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . Furthermore, they identified two important metabolites, prostaglandin F2 and arachidonic acid, and their arachidonic acid metabolism pathway, as vital indicators of LHQW in treating influenza by using serum metabolomics analysis [19]. Traditional Chinese medicine, such as Lianhua Qingwen, has achieved some curative effect in many countries, but its effect is not clear. These data indicate that LHQW prescription protects against the virus attack, and it has been recommended in the treatment of COVID-19 in China [47]. Data were considered statistically significant at p values <0.05. Systematic review of traditional Chinese medicine Lianhua Qingwen in